{
  "abstract": "BACKGROUND: Mogamulizumab (MOGA), an anti-CCR4 monoclonal antibody for mycosis fungoides (MF) and Sézary syndrome (SS), can trigger immune-mediated complications, such as rashes or endocrine disorders. Rheumatological manifestations are rare. OBJECTIVES: To describe cases of inflammatory rheumatism (IR) induced or worsened by MOGA in MF/SS patients. METHODS: A retrospective study collected cases of IR (polymyalgia rheumatica [PMR], rheumatoid arthritis [RA], spondylarthritis, or unclassified IR) in MF/SS patients treated with MOGA across centers of the French Cutaneous Lymphomas Group. Clinical, biological, and imaging data were analyzed. RESULTS: Eleven patients (7 men, 4 women; median age: 72 years) developed IR during (10/11) or soon after (1/11) MOGA treatment. Symptoms included joint pain, stiffness, and functional impairment. All had biological inflammatory syndrome, synovitis on ultrasound, and no autoantibodies. PET-CT confirmed hypermetabolism consistent with intense joint inflammation (SUV=8.0). Management with systemic corticosteroids ± methotrexate led to remission in most cases. MOGA had to be discontinued in 8 patients, with lymphoma control maintained in 6. CONCLUSIONS: MOGA may induce disabling IR, potentially via CCR4+ regulatory T-cell depletion. Early recognition and treatment with corticosteroids ± methotrexate are essential, though MOGA discontinuation may be required.",
  "abstract_shown": true,
  "affiliations": [],
  "article_type": null,
  "arxiv": null,
  "author_total": 14,
  "authors": [
    {
      "name": "Arno Wahler"
    },
    {
      "name": "Sandra Guignard"
    },
    {
      "name": "Gaëlle Quéreux"
    },
    {
      "name": "Olivier Carpentier"
    },
    {
      "name": "Diane Marcé"
    },
    {
      "name": "Elise Dietrich"
    },
    {
      "name": "Matthieu Saintvoirin"
    },
    {
      "name": "Florent Amatore"
    },
    {
      "name": "Ewa Hainaut"
    },
    {
      "name": "Marine de Vicq De Cumptich"
    },
    {
      "name": "Claudia Béjar Ardiles"
    },
    {
      "name": "Olivier Dereure"
    },
    {
      "name": "Marie Beylot-Barry"
    },
    {
      "name": "Saskia Ingen-Housz-Oro"
    }
  ],
  "bibtex": "https://research.draconitic.com/paper/d4xrvsgn5842b.bib",
  "cited_by": 0,
  "doi": "10.1016/j.jbspin.2026.106145",
  "fulltext_url": null,
  "id": "d4xrvsgn5842b",
  "issns": [
    "1297-319X"
  ],
  "landing_url": "https://inserm.hal.science/inserm-05793843v1",
  "language": "en",
  "licence": "CC-BY",
  "licence_label": "CC BY",
  "licence_source": "journal",
  "licence_url": "https://creativecommons.org/licenses/by/4.0/",
  "metadata_licence": null,
  "native_subjects": [
    [
      "hal",
      "0.sdv"
    ],
    [
      "openalex",
      "2745|Rheumatoid Arthritis Research and Therapies"
    ]
  ],
  "openalex": "W7221324071",
  "pdf_url": "https://www.sciencedirect.com/science/article/pii/S1297319X26001144/pdf",
  "pmcid": null,
  "pmid": null,
  "published": "2026-10-12",
  "publisher": "Elsevier Masson",
  "ris": "https://research.draconitic.com/paper/d4xrvsgn5842b.ris",
  "sources": [
    {
      "first_seen": "2026-10-30T12:17:54Z",
      "native_id": "inserm-05793843",
      "source": "hal",
      "url": "https://inserm.hal.science/inserm-05793843v1"
    }
  ],
  "subjects": [
    {
      "field": "biology",
      "origin": "hal:0.sdv",
      "subfield": "general"
    }
  ],
  "title": "Inflammatory rheumatic diseases under mogamulizumab: a multicenter series of 11 cases",
  "title_text": "Inflammatory rheumatic diseases under mogamulizumab: a multicenter series of 11 cases",
  "type": "peer-reviewed",
  "updated_at": "2026-10-30T12:17:54Z",
  "url": "https://research.draconitic.com/paper/d4xrvsgn5842b",
  "venue": "Joint Bone Spine",
  "versions": []
}